No, that is reasonable. It is based on rule of thumb where reagents are controlled for a test of this type (circa $5 cost).
Biotech/health margins are high relative to consumer product. They earn into that right based on high clinical trial risk.
By comparison, molecular tests would cost hundreds and sell for several hundred, still high margin but would be cost prohibitive for replacing or being used alongside fecal immunochemical test (FIT).
100M shares ($15M MC). EV of ~$6M., page-5
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5969 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 5500 | 1 |
View Market Depth
| Last trade - 16.16pm 18/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
Day chart unavailable
